View Cart  

EU Issues Draft Guidance on Marketing Authorization of Transdermal Patches

Manufacturers of transdermal patches should minimize the amount of residual drug substance in the patch as much as possible to avoid patient and environmental safety risks, according to a new European Medicines Agency (EMA) draft guideline.

To View This Article:


Subscribe To International Medical Device Regulatory Monitor

Buy This Article Now

Add this article to your cart for $40.00